Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease - Summary - MDSpire

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

  • By

  • Katie Binley, PhD

  • May 1, 2026

  • 3 min

Share

Objective:

To develop dual-pathway gene therapies for retinal degenerative diseases, specifically targeting geographic atrophy (GA).

Key Findings:
  • Current single-pathway therapies for GA show modest effects and inconsistent improvements in visual function.
  • GA is multifactorial, necessitating simultaneous targeting of multiple pathways.
  • Neuroprotection is critical for achieving meaningful functional outcomes in GA treatment.
Interpretation:

The dual-pathway approach may overcome limitations of existing therapies by providing both anatomical and functional benefits.

Limitations:
  • The study does not provide extensive clinical trial data for IKAR-001.
  • Further research is needed to validate the long-term efficacy of the bicistronic platform.
Conclusion:

Ikarovec's gene therapy represents a promising next-generation treatment for GA and potentially other retinal diseases.

Original Source(s)

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

  • by Katie Binley, PhD

  • May 1, 2026

Related Content

The IGF System and Aging

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

Peripheral retinal degenerations: multimodal imaging–guided risk stratification and clinical decision-making